You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

0

0

▼  3rd Inning 0 outs

Ariad Pharmaceuticals sets ‘poison pill’ provision

NEW YORK — A day after suspending sales of its cancer drug Iclusig, Ariad Pharmaceuticals said it has adopted a shareholder rights plan — often called a “poison pill’ — a move that could help the company fend off a takeover.

Ariad said owners of its shares will be issued the right to buy one additional share for every share they own.

Continue reading below

The plan will go into effect if any person or entity buys a 4.99-percent stake in the company, or if an entity that owns a stake of more than 4.99 percent increases its holdings by at least half a percent.

Shareholder rights plans allow existing shareholders to acquire more stock at a discounted rate, and are typically used to discourage a takeover by an outside entity.

They are designed to thwart anyone who buys a big chunk of its stock without board approval.

The Cambridge company said it adopted the plan to protect $307.7 million in net operating loss carry forwards at the end of 2012 and $17.8 million in research tax credits. Those could be used to offset some of its taxable income or reduce tax liabilities.

Ariad said its ability to use those credits would be reduced significantly if the company’s ownership structure changes under tax law.

Shareholders will be able to vote on the plan at the company’s annual meeting in 2014. The shareholder rights are scheduled to expire on Oct. 31, 2014.

Ariad’s biggest shareholder is Sarissa Capital Management, a Connecticut-based hedge fund launched earlier this year by Alexander Denner, who previously was a health care executive with activist investor Carl Icahn.

Sarissa disclosed holdings of 11.5 million shares, a 6.2 percent stake on Tuesday, purchased between Oct. 9 and 22.

Boston-based hedge fund Camber Capital Management LLC, which focuses on health care, also disclosed a stake of 10 million shares, or 5.4 percent, on Oct. 23, none of which was owned as recently as June 30, according to regulatory filings.

Ariad also said it is delaying its third-quarter report to the morning of Nov. 12. It was originally scheduled to post results on Nov. 6.

On Thursday, Ariad suspended sales of Iclusig, a leukemia drug, because of heightened concerns that patients could suffer from life-threatening blood clots.

The Food and Drug Administration says 48 percent of patients treated with the drug in an early-stage trial and 24 percent who took the drug in a mid-stage trial have suffered serious side effects, including heart attacks and strokes, and some patients died as a result.

Iclusig’s label warns about those side effects, but in October Ariad said they were occurring at a higher rate than it had expected.

The company said it wants to resume selling the drug and is talking to the FDA about ways to manage its risks.

Ariad Pharmaceuticals Inc. shares fell 44 percent to $2.20 on Thursday, down 87 percent from their closing price on Oct. 8.

The stock gained 38 cents, or 17.3 percent, to close at $2.58 Friday.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.